Loading...
In recent randomized trials of obicetrapib, a non–FDA-approved cholesteryl ester transfer protein inhibitor, treatment lowered atherogenic lipoproteins and raised high-density lipoprotein cholesterol (HDL-C) at 1-year follow-up. To evaluate the impact of obicetrapib (10 mg/day) on major adverse cardiovascular events (MACE; coronary heart disease death, myocardial infarction, ischemic stroke, or coronary revascularization), researchers pooled patient data from two manufacturer-supported, randomized, 1-year studies.
Nearly 2900 patients were included (mean age, 66; 36% female); 82% had atherosclerotic cardiovascular disease, and 27% had heterozygous familial hypercholesterolemia. At baseline, median low-density lipoprotein cholesterol (…